Fertility awareness methods (FAMs) are effective methods of family planning that make use of clinical signs to monitor female fertility. 1 They can provide a valid option for women for whom other methods are not desirable because of medical contraindications or environmental, philosophical, or religious conflicts.
However, difficult signs such as confusing cervical mucus or erratic basal body temperature make the use of these methods difficult in some cases. Thus new technological approaches are sought to make FAMs easier, more effective, and cheaper. 2 The purpose of this study was to assess the feasibility of using a urinary luteinizing hormone (LH)-surge identification kit (sensitivity, 20 mIU/mL; $1.00/kit; BTNX Inc., Toronto, ON, Canada) as an adjunct to identify the infertile phase after ovulation when facing challenging scenarios.
Methods
The study consisted of a block allocation, crossover, 2-arm methodology ( Figure 1 ). We allocated half of the participants to use the LH kit concurrently with a FAM during a menstrual cycle (arm 1); subsequently, a cycle with a FAM-only method was used (arm 2) (group A). The other half of participants started with opposite sequence (group B). Participants were allocated to one of the groups depending on their order of enrollment into the study. The main investigator (RL) flipped a coin to assign the first participant to a specific group, and the next participant was assigned to the alternate group, and so on. Allocation assignment occurred in similar pattern for each participant until enrolment completed. This method was used to account for a potential learning effect since each participant was exposed to the 2 arms. Ethical approval for this study was granted by the ethics and research boards of the Ottawa Hospital and Bruyere Continuing Care Hospital in Ottawa, Canada.
Each woman started once-a-day testing on the sixth day following her first day of menses until she developed a surge in LH (ie, a positive result per test's instructions) and continuing until she received negative results for 3 consecutive days. On the third day following the last day of a positive urine LH test, a serum progesterone test was done to confirm presence of the luteal phase (serum progesterone concentration Ͼ10 nmol/L). In the FAM-only cycles (arm 2), the participants proceeded with the progesterone test as soon as the infertile phase occurred after ovulation, as defined by the FAM being used. The 2 arms were compared with regard to accuracy of identification (yes/ no) of the luteal phase. Statistical analysis to compare the 2 arms consisted of creating a contingency table and applying an exact McNemar test. Participants trying to get pregnant or currently or recently using (6 months) of any type of hormonal contraception were excluded.
Results
Forty women were assessed for enrollment; 29 fulfilled the criteria and 6 were lost to follow-up (loss of interest, n ϭ 2; moved away, n ϭ 1; medical reasons, n ϭ 3). The 23 women enrolled had the following characteristics: age range 20 to 48 years; mostly white (n ϭ 18); using mucus-based method (n ϭ 14) or mucus temperature (n ϭ 9); all Canadian; and all with a high school education or higher.
Each woman supplied information on 2 cycles, for a total of 46 cycles. Mean cycle length was 29.3 days. For the FAM cycles, mean length was 29 days. For the cycles using LH kits, mean length was 29.5 days. There was no significant difference between cycle lengths for each woman. All the women correctly identified the luteal phase using the LH kit as an adjunct. Three phases were not correctly identified using FAM only, giving a 0.13 absolute difference (Table 1) . A mean of 15 kits were used per cycle.
Discussion
In this pilot study, we found that the use of urinary LH kits with a sensitivity of 20 mIU/mL may provide a useful adjunct for those women with difficulty identifying their postovulation period. This study did not, however, attempt to develop a new FAM method but to explore an option for those women who need to gain extra confidence. There are a few limitations to our study. LH kits may not provide a 100% confirmation in clinical circumstances outside our population of study given the variability in the LH secretion during the cycle 3 ; such scenarios may include, for instance, breastfeeding, very long anovulatory cycles, extremely short LH surges, and premenopause. In addition, this study did not address the beginning of the fertile phase, which still requires the use of a reliable first indicator for those women who do not want to conceive. Theoretically, the above-mentioned problems could be easily addressed with the development of simpler and cheaper urinary tests or monitors that use the metabolites of estrogen and progesterone. 4 Future promising research could involve the use of several urinary metabolites (estradiol, LH, progesterone) 2 with or without the combination of clinical signs such as cervical mucus to ascertain both the fertile and infertile phases of the menstrual cycle. This pilot study could be used as an example for future research. 
